Speakers
-
Balicer Ran D
Clalit Health Services, IsraelRan Balicer is the Founding Director of the Clalit Research Institute, the WHO Collaborating Center on Non-Communicable Diseases Research, Prevention and Control. In Parallel, he serves as Director of the newly formed Innovation Division for Clalit - Israel's largest healthcare organization. In these roles, he is responsible for strategic planning of novel organization-wide interventions for improving healthcare quality, reducing disparities and increasing effectiveness. These include the introduction of innovative data-driven tools into practice - predictive modeling, real-life effectiveness studies, decision support tools and proactive care models.
Prof Balicer also serves as a Full Professor and as Track Director in the MPH program at the Ben-Gurion University, Israel. His research is focused on the study of extensive clinical databases in care provision and policymaking, health systems integrated care, and quality management.
Prof. Balicer serves as Chair of the Israeli Society for Quality in Healthcare and as an Advisor to Israeli Ministry of Health. He also serves as a Board Member of the International Foundation for Integrated Care (IFIC) and of the European Federation of Medical Informatics (EFMI).
Prof. Balicer serves in senior advisory groups to the World Health Organization (WHO) Regional Office for Europe - including the Region’s Senators Group, and is involved in projects focusing on chronic diseases monitoring, prevention and control, and healthcare systems redesign.
-
-
-
Dean Jeff
Google, USAJeff Dean joined Google in 1999 and is currently a Google Senior Fellow and SVP of Google AI and Health, overseeing Google’s research and healthcare teams. He and his collaborators are working on machine learning and AI techniques for speech recognition, computer vision, language understanding, robotics, healthcare and various other tasks. He is a co-designer and co-implementor of many important software systems, including MapReduce, BigTable, and Spanner, and the open-source TensorFlow system for machine learning.
Jeff received a Ph.D. in Computer Science from the University of Washington in 1996 and a B.S. in computer science & economics from the University of Minnesota in 1990. He is a member of the U.S. National Academy of Engineering, and of the American Academy of Arts and Sciences, a Fellow of the Association for Computing Machinery (ACM), a Fellow of the American Association for the Advancement of Sciences (AAAS), and a winner of the ACM Prize in Computing and the Mark Weiser Award.
-
Elhadad Noémie
Columbia University, USA -
Engelhardt Barbara
Princeton, USA -
Gentleman Robert
23andme, USADr. Robert Gentleman joined 23andMe in 2015 as vice president of computational biology. In this role, he focuses on the exploration of how human genetic and trait data in the 23andMe database can be used to identify new therapies for disease. Dr. Gentleman will specifically focus on collaborating with Dr. Richard Scheller and the recently formed therapeutics group.
Most recently, Dr. Gentleman served as Senior Director of Bioinformatics and Computational Biology at Genentech. Prior to this role, he was head of the computational biology department at the Fred Hutchinson Cancer Research Center. Dr. Gentleman served as a professor at Harvard University, the University of Auckland, and the University of Waterloo.
He has been awarded the Benjamin Franklin Award, a recognition for Open Access in the Life Sciences presented by the Bioinformatics Organization and is Fellow of the International Society for Computational Biology (ISCB). Dr. Gentleman, along with Ross Ihaka at the University of Auckland, is also recognized as one of the originators of the R programming language, a widely-used programming language software environment for statistical computing and graphics. Dr. Gentleman was one of the founders of the Bioconductor Project.
Dr. Gentleman earned a Bachelor of Science in Mathematics from The University of British Columbia and holds a Doctor of Philosophy, Ph.D., in Statistics from the University of Washington.
-
Hernán Miguel
Harvard University, USA -
Kohane Isaac
Harvard Medical School, USAIsaac Kohane, MD, PhD is the inaugural Chair of the Department of Biomedical Informatics and the Marion V. Nelson Professor of Biomedical Informatics at Harvard Medical School. He develops and applies computational techniques to address disease at multiple scales—from whole healthcare systems as “living laboratories” to the functional genomics of neurodevelopment with a focus on autism. Kohane’s i2b2 project is currently deployed internationally to over 120 major academic health centers to drive discovery research in disease and pharmacovigilance (including providing evidence on drugs which ultimately contributed to “boxed warning” by the FDA). Dr. Kohane has published several hundred papers in the medical literature and authored a widely-used book on Microarrays for an Integrative Genomics. He is a member of the Institute of Medicine and the American Society for Clinical Investigation.
-
Lyons Ronan
HDR UKRonan A Lyons, FFPH (UK), FFPHM (RCPI), MD is Professor of Public Health and Director of the National Centre for Population Health and Wellbeing Research at Swansea University, Director of the Wales and Northern Ireland site of Health Data Research UK (HDRUK), and Adjunct Professor at Monash University, Australia. He leads the Modernising Public Health Research theme for HDRUK.
Prof Lyons graduated in medicine from Trinity College Dublin, Ireland in 1983. After several years of hospital medicine, he specialised in public health and epidemiology prior to moving to Wales as a public health consultant and part-time ED clinician. In 1998, he moved to academia, initially with the University of Wales College of Medicine in Cardiff and in 2005 to the newly created Swansea University Medical School.
Prof Lyons pioneered the development of privacy-protecting whole of population electronic cohorts in the UK, including the development of the Wales Electronic Cohort for Children (1m children) and the creation of a unique, award-winning, household/individual data linkage system for the evaluation of the impact of non-healthcare interventions on health. His research interests are quite wide-ranging and include the influences of wider health determinants on health and wellbeing throughout the life-course, the role of the build environment on health, multi-morbidity and the evaluation of natural experiments.
He leads the analysis platform for the MRC Dementias Platform UK (DPUK) initiative, providing global remote access to multi-modal data on more than 2 million people from more than 30 cohorts. DPUK will shortly be linked to similar initiatives across the globe, supported by a grant from a major philanthropist.
Prof Lyons has also had a long-term interest in the neglected field of injury prevention and control. He has played a substantial role in the development of surveillance systems to measure the incidence, outcomes and burden of injuries and to test the efficacy of policies and interventions. Since 2012, he has chaired the International Collaborative effort on Injury Statistics and Methods (US National Centre for Health Statistics) and has been instrumental in creating a global network to measure the individual, family and population burden of injuries.
He was elected a Fellow of the Learned Society of Wales in 2012.
-
Obermeyer Ziad
UC Berkeley, USAZiad Obermeyer is an Associate Professor (acting) at UC Berkeley who works at the intersection of machine learning and health. His research seeks to understand and improve decision making in public policy and clinical medicine, and drive innovations in health research. He was previously an Assistant Professor at Harvard Medical School and an emergency physician at the Brigham and Women’s Hospital, where he received the Early Independence Award from the Office of the Director of the National Institutes of Health, and the Young Investigator Award from the Society for Academic Emergency Medicine. His work has been published in Science, The New England Journal of Medicine, JAMA, The BMJ, and Health Affairs, and his research is supported by the National Institutes of Health, the Robert Wood Johnson Foundation, and the Laura and John Arnold Foundation. Prior to his career in medicine, he earned an M.Phil. from Cambridge in the history and philosophy of science, and worked as a consultant to pharmaceutical and global health clients at McKinsey & Co. in New Jersey, Geneva, and Tokyo. He is a graduate of Harvard College (magna cum laude) and Harvard Medical School (magna cum laude)
-
Ramoni Rachel
Million Veterans program, USARachel B. Ramoni, D.M.D., Sc.D., has been Chief Research and Development Officer (CRADO) for VA since January of 2017. She received her degrees in both dentistry and epidemiology from Harvard. Rachel has a passion for leading large, multidisciplinary endeavors towards practical impacts. Prior to her work at VA, she was at New York University and Harvard Medical School where she directed two major projects from the Department of Biomedical Informatics under the leadership of Zak Kohane. The first, called SMART, focused on practical solutions for meaningful healthcare interoperability, and resulted in SMART on FHIR, a technology that is being used by major vendors like Apple, Cerner, and Epic. The second, the Undiagnosed Diseases Network (UDN), brings together clinical and research experts from across the U.S. to solve challenging medical mysteries using advanced technologies. The Boston Globe called the network a "powerful new way to diagnose mystery illnesses." As of March 2019, the Network had diagnosed 283 of what the New York Times referred to as “the toughest cases, patients whose symptoms have defied explanation”. As CRADO, Rachel oversees VA's nationwide research enterprise, encompassing some 2,000 active projects at more than 100 sites, including the Million Veteran Program. Her office’s total budget in fiscal 2018 is $779 million.
-
Rohan Hastie
Metabolon, USADr. Rohan F. Hastie has served as president and CEO at Metabolon since May 2018. He leads the company’s vision to harness the power of its Precision Metabolomics™ Platform to provide biological insights of disease state and physiological reactions in the present state. As the global leader in metabolomics, Metabolon offers the world’s largest – and continuously growing metabolomics knowledge base. The company’s deep metabolomic insights are addressing some of the most difficult and pressing questions in the life sciences, helping to advance success in the biopharma, consumer products, and academic research sectors.
Dr. Hastie is a proven Life Sciences executive with 20 years of leadership experience. He joined Metabolon in 2017 as chief business officer to oversee critical strategic initiatives within the company's precision medicine, population health, pharmaceutical and life sciences businesses, and to guide global commercial development.
Prior to joining Metabolon, he was president of Arrow Life Sciences & Healthcare, a consulting firm specializing in commercialization and operational excellence for life sciences companies. He also held various senior leadership positions in diagnostics and corporate development at Hologic, Inc., including president of Hologic Diagnostics where he grew the business into one of the world’s leading diagnostics companies with more than 1800 employees and $1.25 billion in annual revenue. Earlier in his career, Dr. Hastie worked at the strategy consulting company PA Consulting Group in their Life Sciences and Technology group, consulting for a wide range of companies in the pharmaceutical, biotechnology and diagnostics industries. He earned his Ph.D. in molecular genetics from Queen Elizabeth Medical School in Birmingham, England and a degree in biological sciences from the University of Birmingham.
-
Ron Milo
Weizmann Institute of Science -
Saria Suchi
Johns Hopkins University, USA -
Segal Eran
Weizmann Institute of ScienceEran Segal is a Professor at the Department of Computer Science and Applied Mathematics at the Weizmann Institute of Science, heading a lab with a multi-disciplinary team of computational biologists and experimental scientists in the area of Computational and Systems biology. His group has extensive experience in machine learning, computational biology, probabilistic models, and analysis of heterogeneous high-throughput genomic data. His research focuses on Microbiome, Nutrition, Genetics, and their effect on health and disease. His aim is to develop personalized nutrition and personalized medicine.
Prof. Segal published over 140 publications, and received several awards and honors for his work, including the Overton prize, awarded annually by the International Society for Bioinformatics (ICSB) to one scientist for outstanding accomplishments in computational biology, and the Michael Bruno award. He was recently elected as an EMBO member and as a member of the young Israeli academy of science.
Before joining the Weizmann Institute, Prof. Segal held an independent research position at Rockefeller University, New York.
Education: Prof. Segal was awarded a B.Sc. in Computer Science summa cum laude in 1998, from Tel-Aviv University, and a Ph.D. in Computer Science and Genetics in 2004, from Stanford University.
Lab website: http://genie.weizmann.ac.il
-
Shah Nigam
Stanford University, USADr. Nigam Shah is Associate Professor of Medicine (Biomedical Informatics) at Stanford University, and Associate CIO for Data Science at the Stanford Hospital. Dr. Shah's research led to the creation of the USA's only bedside consult service that provides a clinician with an on-demand summary of similar patients in terms of the treatment choices made and observed outcomes (http://greenbutton.stanford.edu). Dr. Shah also leads Stanford Hospital's Program for Artificial Intelligence (AI) in Healthcare, which aims to bring AI technologies to the clinic, safely and ethically. He is an inventor on several patents and patent applications on using ontologies for data mining, and has co-founded two companies. Dr. Shah received the AMIA New Investigator Award for 2013, was elected into the American College of Medical Informatics (ACMI) in 2015 and inducted into the American Society for Clinical Investigation (ASCI) in 2016. He holds an MBBS from Baroda Medical College, India, a PhD from Penn State University and completed postdoctoral training at Stanford University. More at: https://med.stanford.edu/profiles/nigam-shah
-
Shalev Varda
Maccabi Health Services, Israel -
Shalit Uri
Technion, Israel -
Tanay Amos
Weizmann Institute of Science -
Toledano Eyal
Zebra medical, IsraelEyal Toledano is co-founder and CTO of Zebra Medical Vision; Eyal focuses on innovation in medical imaging machine vision. Graduated with Master of Science from the MIT Media Lab. Eyal served for more than 8 years as the CTO and Advanced Technology GM for Samsung Israel R&D (STRI/Yakum). Before co-founding the Israeli R&D of Samsung Eyal was leading the development of challenging projects at Sun Microsystems. Eyal completed 7 years of military service in the IDF Elite Intelligence Technologies. Eyal still hacks code every day, loves to make morning sandwiches to 5-year-old Yuval, enjoys scuba diving, tennis and punk music.
-
Yaniv Erlich
Chief Science Officer, MyHeritage and Associate Professor of Computer Science, Columbia UniversityDr. Yaniv Erlich is the Chief Science Officer of MyHeritage.com and an Associate Professor of Computer Science and Computational Biology at Columbia University (leave of absence). Prior to these positions, he was a Fellow at the Whitehead Institute, MIT. Dr. Erlich received his bachelor’s degree from Tel-Aviv University, Israel (2006) and a PhD from the Watson School of Biological Sciences at Cold Spring Harbor Laboratory (2010). Dr. Erlich’s research interests are computational human genetics. Dr. Erlich is a TEDMED speaker (2018), the recipient of DARPA’s Young Faculty Award (2017), the Burroughs Wellcome Career Award (2013), Harold M. Weintraub award (2010), the IEEE/ACM-CS HPC award (2008), and he was selected as one of 2010 Tomorrow’s PIs team of Genome Technology.
-
Zhengming Chen
Biobank Kadoorie China, University OxfordProfessor Zhengming Chen is the lead principal investigator of the China Kadoorie Biobank (CKB). He qualified in medicine at the Shanghai Medical University in 1983 and gained his DPhil in Epidemiology at the University of Oxford in 1993. He currently holds the position of Professor of Epidemiology at the University of Oxford, and honorary professorships of several universities & institutes (eg, Peking Union Medical College, Fudan University and Chinese Academy of Sciences). He is the founding co-director of the China Oxford Centre for International Health Research.
His main research has focused on the environmental, lifestyle and genetic determinants of chronic disease, development of evidence-based medicine and efficient strategies for chronic disease control in developing countries. Over the last 25 years, he has led large placebo-controlled trials involving in total 60,000 acute heart attacks, 20,000 strokes and 15,000 cancers, leading to major changes of international guidelines and new US FDA drug labelling. He has also led large cohort studies of the relevance to health of tobacco, alcohol, adiposity, blood pressure, and diet. In particular, he initiated, and has led the CKB (www.ckbiobank.org) from its inception in 2002, which includes 512,000 adults enrolled during 2004-08 from 10 diverse areas across China. He has published over 320 peer-reviewed papers and also sits on various research committees.
-
-
In collaboration with
Sponsor:
The Chorafas Institute for Scientific Exchange
Israel Institute for Advanced Studies
Organizing committee
- Eran Segal
Weizmann Institute of Science - Joao Monteiro
Chief Editor, Nature Medicine
Conference Coordinator
Inbal Azoulay
inbal.azoulay@weizmann.ac.il